Corticosteroid derivatives - IVAX

Drug Profile

Corticosteroid derivatives - IVAX

Alternative Names: Soft steroids - IVAX

Latest Information Update: 07 Aug 2007

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator IVAX Corporation
  • Developer IVAX Drug Research Institute
  • Class
  • Mechanism of Action Steroid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Allergic conjunctivitis; Allergic rhinitis; Emphysema; Inflammation

Most Recent Events

  • 27 Jan 2006 IVAX Corporation has been acquired by Teva Pharmaceutical Industries
  • 14 Jun 2001 Preclinical development for Emphysema in Hungary (Inhalation)
  • 31 Dec 1999 Preclinical development for Allergic conjunctivitis in Hungary (Ophthalmic)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top